Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minDescending Triangle
Daily trend turns down below $28.69
Key levels
Resistance$32.06
Resistance$31.21
Support$30.41
Support$29.60
Latest news & SEC filings
AnalystSmith & Nephew Sees Analyst Target Change at UBS
DealSmith & Nephew halts combination discussions with Johnson & Johnson orthopedics business, trims 2026 forecast
EarningsSmith+Nephew Q3 revenue up 3.4% to $1.551B, half of $500M buyback done
All SNN news →Smith & Nephew is a medical technology company that repairs, regenerates, and replaces soft and hard tissue. It operates through three global units: Orthopaedics (hip, knee, and shoulder implants, trauma products, and robotic surgery systems), Sports Medicine & ENT (instruments for soft tissue repair and ear, nose, and throat procedures), and Advanced Wound Management (products for hard-to-heal wounds). Its customers are hospitals, surgeons, and healthcare providers, and it sells in about 100 countries.
Based on the company's 20-F filed Mar 16, 2026.
NYSE · Healthcare
SEPT Low Target
$32.32
SEPT Mid Target
$32.32
SEPT High Target
$32.32
Analyst Consensus
$32.32
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SNN.
Start Free Trial →Valuation Verdict
FAIR
Methods Used
P/E Forward, Analyst Consensus
Fair Value
$33.94
60
Moat Score
NARROW
6/9
Piotroski Score
4.9
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
BUYING
1 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
6.1%
3yr Revenue CAGR
5.7%
EPS Growth YoY
52.34%
FCF Growth YoY
N/A%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for SNN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:22 | $31.15 | 2,120 | $$66K | SELL |
| 20:58:33 | $31.16 | 1,200 | $$37K | MIDPOINT |
| 20:55:53 | $31.14 | 1,037 | $$32K | BUY |
| 20:35:32 | $31.02 | 1,000 | $$31K | MIDPOINT |
| 20:23:51 | $31.08 | 1,000 | $$31K | BUY |
5 dark pool trades shown · $$198K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for SMITH & NEPHEW PLC (SNN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings intelligence, and a complete investment thesis with entry and exit recommendations.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SMITH & NEPHEW PLC (SNN) is at $31.15, down 2.69% (-$0.86) at the Nov 6, 2026 close.
Latest SNN news — Nov 5, 2026: Smith & Nephew Sees Analyst Target Change at UBS · Nov 4, 2026: Smith & Nephew halts combination discussions with Johnson & Johnson orthopedics business, trims 2026 forecast
The average analyst price target for SNN is $32.32, ranging from $32 to $32.
Analyst ratings for SNN: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
SNN last reported on Aug 4, 2026: EPS $0.95 vs $0.94 expected — a beat of 0.7%.
Yes. SNN's dividend yield is 1.27%.
SMITH & NEPHEW PLC reported $3.1B of debt and $557M of cash (Dec 31, 2025).
Support: $30.41, $29.60, $28.69. Resistance: $31.21, $32.06, $32.91.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 5, 2026: Smith & Nephew Sees Analyst Target Change at UBS · Nov 4, 2026: Smith & Nephew halts combination discussions with Johnson & Johnson orthopedics business, trims 2026 forecast · Nov 4, 2026: Smith+Nephew Q3 revenue up 3.4% to $1.551B, half of $500M buyback done